Editorial Perspectives On Patient Recruitment

1. Takeda's Diversity Strategy Pays Off For Phase 3 Trial 3/12/2025

   LaShell Robinson, head of global feasibility and trial equity at Takeda explains how the company’s Phase 3 trial for a psoriasis drug ended enrollment well before it’s goal and achieved some impressive diversity metrics. 

2. The Scoop On SCOPE 2/7/2025

   Chief Editor Dan Schell summarizes some of his favorite quotes and learnings from the 2025 SCOPE Summit. Spoiler alert … Not everything is about AI these days. 

3. We're Looking At Patient Recruitment All Wrong 1/22/2025

   Leanne Woehlke, a 30-year veteran of the clinical research industry, says our standard patient recruitment efforts are lacking one key element — a focus on the patient’s needs. 

4. Let's Fix The Tax Burden On Clinical Trial Participants 12/10/2024

   We all know that patient retention is lowered once a participant realizes the tax implications of being in a clinical trial. But taxes should be the last thing they have to worry about, so why can’t we get some changes made? 

5. 2024: Familiar Problems & Encouraging Progress 11/27/2024

   For part 1 of my 2024 recap, I asked various industry experts what stood out to them this year regarding the clinical trials industry. They mentioned significant challenges related to site capacity, enrollment, workforce changes, and trial complexity, but they also seemed encouraged with some of the efforts and emerging solutions that will address these issues.

6. Not A Bad First Year 11/11/2024

   Dan Schell, chief Editor or Clinical Leader, summarizes his first year in this role and highlights some of his key takeaways and lists some of the people who have helped him better understand the clinical trials ecosystem. 

7. Key Takeaways From Clinical Trial Diversity Discussion 9/24/2024

   During the Clinical Leader Live, The Diversity Mandate: Effective Strategies in Clinical Trials”, we discussed everything from the guidance, to diversity action plans, to the need for better data on race, ethnicity, and identity. In this article, we also share 25 questions audience members had regarding this hot topic.

8. Government Contract Advances Walgreens In Clinical Space 8/1/2024

   Walgreen’s new $25 million deal with BARDA (Biomedical Advanced Research and Development Authority) is a huge win for the pharmacy chain. John Campbell, head of DCTs at Walgreens, explains the ins and outs of the study and what could be next for the company regarding its clinical trials division.

9. Siteless DCTs Are Real … And Happening Now 6/20/2024

   Siteless DCTs (decentralized trials) are rare, but Praxis Precision Medicines is running one now for patients with essential tremor (ET). Marcio Souza, PharmD, the company’s president and CEO, talks about why they chose this model and the surprising speed at which it is progressing.

10. How Takeda Leverages Cultural Competency Training To Improve Diversity 3/14/2024

    Karen Correa, VP, head global clinical operations at Takeda, details some uncommon ways the pharma is tackling the problem of diversity in clinical trials.